Taken altogether, these data, similarly to what observed in mice, imply that AIM2 in COPD adenocarcinoma patients could underlie lung inflammation typical of smoking patients who have a higher hazard ratio to survive less than non-smoker, non-COPD adenocarcinoma patients. Here, AIM2 is linked to adenocarcinoma.